{"links":{"html":"https://www.erudio.com/reports/monumental-6-nct06208150","json":"https://www.erudio.com/reports/monumental-6-nct06208150.json","markdown":"https://www.erudio.com/reports/monumental-6-nct06208150.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"monumental-6-06208150"}},"request":"https://www.erudio.com/contact?report=monumental-6-06208150"},"offer":{"cited_commentary_sources":42,"verified_hcp_statements":539,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1950,"identity_verified_people":29,"optional":true,"price_per_verified_person_usd":15,"price_usd":435,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1950,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"monumental-6-nct06208150"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=monumental-6-06208150","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/monumental-6-nct06208150","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"deep","size_rule":"Deep: 301+ verified statements","updates_usd":{"3_months":3400,"6_months":4900,"12_months":6800},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T18:16:20.310116Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":16,"no_commentary_found":0},"aspects":[{"claim_count":10,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":8,"title":"Primary endpoint: Progression Free Survival (PFS)"},{"claim_count":5,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":18,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":10,"title":"Population and setting"},{"claim_count":16,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":9,"title":"The comparison"},{"claim_count":24,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":11,"title":"Safety and tolerability"},{"claim_count":7,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":7,"title":"Design and conduct"},{"claim_count":28,"coverage":"discussed","id":"A1","source_count":11,"title":"Infection prevention and the burden of ongoing immune support"},{"claim_count":36,"coverage":"discussed","id":"A2","source_count":15,"title":"Finite duration, treatment cessation and response-dependent dose spacing"},{"claim_count":35,"coverage":"discussed","id":"A3","source_count":9,"title":"Selective dual targeting for high-risk and visceral extramedullary disease"},{"claim_count":33,"coverage":"discussed","id":"A4","source_count":5,"title":"Choosing CAR T or a bispecific at the relapse decision"},{"claim_count":51,"coverage":"discussed","id":"A5","source_count":10,"title":"Antigen sequence, holding treatment and bridging before or after CAR T"},{"claim_count":51,"coverage":"discussed","id":"A6","source_count":13,"title":"Anti-CD38 refractoriness, comparator suitability and alternative-study interpretation"},{"claim_count":38,"coverage":"discussed","id":"A7","source_count":11,"title":"Tal-P rationale versus the incremental value of an IMiD or CELMoD on another backbone"},{"claim_count":36,"coverage":"discussed","id":"A8","source_count":6,"title":"Selective conventional, transplant and ADC alternatives"},{"claim_count":27,"coverage":"discussed","id":"A9","source_count":8,"title":"Community access, step-up dosing, CRS prevention and restarting treatment"},{"claim_count":18,"coverage":"discussed","id":"A10","source_count":4,"title":"Patient education, nutrition, referrals and practical support"}],"counts":{"cited_sources":43,"claims_by_expression_type":{"comparison":42,"experience":41,"interpretation":111,"opinion":173,"primary_context":5,"question":39,"restatement":50,"uncertainty":34,"unspecified":44},"claims_by_kind":{"interpretation":17,"limitation":5,"protocol_statement":2,"source_observation":515},"clinician_statements":334,"evidence_units":294,"findings":12,"organisational_accounts":6,"people_cited":39,"people_identity_verified":29,"people_total":41,"screened_sources":67,"verified_claims":539},"findings_index":[{"id":"F1","structure":{"claims":48,"claims_by_group":{"comparisons":2,"experience":1,"questions":6,"restated":15,"views":24},"has_counterview":true,"limitations":2,"links":{"context":4,"support":50},"ma_question":true,"named_voices":19,"passages":34,"sources":22,"sources_by_kind":{"commentary":15,"media":7}},"title":"Emphatic interim-result enthusiasm does not settle combination selection or establish superiority to every early-relapse option"},{"id":"F2","structure":{"claims":64,"claims_by_group":{"comparisons":13,"experience":4,"questions":12,"restated":7,"views":28},"has_counterview":true,"limitations":3,"links":{"context":3,"support":69},"ma_question":true,"named_voices":17,"passages":42,"sources":11,"sources_by_kind":{"commentary":2,"media":9}},"title":"BCMA-first preferences reflect GPRC5D tolerability concerns, with selective exceptions and differing assessments of reversibility"},{"id":"F3","structure":{"claims":33,"claims_by_group":{"comparisons":2,"experience":6,"questions":1,"restated":3,"views":21},"has_counterview":true,"limitations":2,"links":{"context":2,"support":33},"ma_question":true,"named_voices":15,"passages":22,"sources":12,"sources_by_kind":{"commentary":4,"media":8}},"title":"Infection risk makes prevention, replacement access and continuing supportive-care burden central to adoption"},{"id":"F4","structure":{"claims":39,"claims_by_group":{"comparisons":1,"experience":8,"questions":10,"restated":6,"views":14},"has_counterview":true,"limitations":4,"links":{"context":4,"support":40},"ma_question":true,"named_voices":16,"passages":30,"sources":15,"sources_by_kind":{"commentary":7,"media":8}},"title":"Finite duration and response-adapted spacing attract support, but the optimal stopping point and preserved benefit remain uncertain"},{"id":"F5","structure":{"claims":80,"claims_by_group":{"comparisons":5,"experience":3,"questions":13,"restated":14,"views":45},"has_counterview":true,"limitations":3,"links":{"context":10,"support":87},"ma_question":true,"named_voices":15,"passages":61,"sources":13,"sources_by_kind":{"commentary":4,"media":9}},"title":"Dual targeting draws particular interest in high-risk and visceral extramedullary disease, without answering who needs both agents"},{"id":"F6","structure":{"claims":39,"claims_by_group":{"comparisons":4,"experience":2,"questions":4,"restated":3,"views":26},"has_counterview":true,"limitations":3,"links":{"context":1,"support":43},"ma_question":true,"named_voices":8,"passages":22,"sources":5,"sources_by_kind":{"commentary":1,"media":4}},"title":"CAR T versus bispecific preferences differ with risk tolerance, disease tempo, fitness and the value placed on treatment-free time"},{"id":"F7","structure":{"claims":68,"claims_by_group":{"comparisons":3,"experience":6,"questions":13,"restated":8,"views":38},"has_counterview":true,"limitations":4,"links":{"context":3,"support":78},"ma_question":true,"named_voices":14,"passages":50,"sources":10,"sources_by_kind":{"commentary":2,"media":8}},"title":"Sequencing and bridging choices remain conditional on target exposure, manufacturing access, disease control and weak comparative evidence"},{"id":"F8","structure":{"claims":53,"claims_by_group":{"comparisons":4,"experience":0,"questions":4,"restated":13,"views":32},"has_counterview":true,"limitations":2,"links":{"context":2,"support":59},"ma_question":true,"named_voices":14,"passages":38,"sources":12,"sources_by_kind":{"commentary":4,"media":8}},"title":"Prior anti-CD38 exposure versus refractoriness changes comparator relevance, daratumumab reuse and interpretation of alternative bispecific evidence"},{"id":"F9","structure":{"claims":48,"claims_by_group":{"comparisons":3,"experience":3,"questions":6,"restated":11,"views":25},"has_counterview":true,"limitations":3,"links":{"context":2,"support":49},"ma_question":true,"named_voices":14,"passages":30,"sources":12,"sources_by_kind":{"commentary":1,"media":11}},"title":"Tal-P has a distinct development rationale; skepticism about adding pomalidomide to Tal-Dara does not negate it"},{"id":"F10","structure":{"claims":36,"claims_by_group":{"comparisons":3,"experience":4,"questions":3,"restated":4,"views":22},"has_counterview":false,"limitations":2,"links":{"context":1,"support":38},"ma_question":true,"named_voices":5,"passages":19,"sources":6,"sources_by_kind":{"commentary":1,"media":5}},"title":"Conventional triplets, transplant, ADCs and mechanism-switching alternatives remain selective options rather than uniformly displaced treatments"},{"id":"F11","structure":{"claims":25,"claims_by_group":{"comparisons":2,"experience":6,"questions":1,"restated":3,"views":13},"has_counterview":false,"limitations":2,"links":{"context":2,"support":27},"ma_question":true,"named_voices":5,"passages":17,"sources":7,"sources_by_kind":{"commentary":3,"media":4}},"title":"Community delivery depends on shared care, practical prophylaxis, monitoring infrastructure and access—not efficacy alone"},{"id":"F12","structure":{"claims":17,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":4,"views":12},"has_counterview":false,"limitations":2,"links":{"context":1,"support":21},"ma_question":true,"named_voices":3,"passages":11,"sources":3,"sources_by_kind":{"media":3}},"title":"Patient education, nutrition surveillance, specialist support and financial burden shape whether treatment remains acceptable"}],"medical_affairs_question":"Which patients need Tal-Tec rather than Tal-P, a single-agent bispecific, CAR T or a conventional alternative, and what duration and supportive-care burden make that choice acceptable?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Efficacy enthusiasm and the limits of treatment-selection inferences"},{"id":"section-2","level":2,"title":"Why favor BCMA first—and when might GPRC5D come first?"},{"id":"section-3","level":2,"title":"How infection risk and prophylaxis affect treatment acceptability"},{"id":"section-4","level":3,"title":"Scope and coverage"},{"id":"section-5","level":2,"title":"When should bispecific treatment stop, and when should doses be spaced?"},{"id":"section-6","level":3,"title":"Which high-risk patients need dual targeting, and how much risk remains?"},{"id":"section-7","level":3,"title":"Scope and interpretation limits"},{"id":"section-8","level":2,"title":"How do toxicity, treatment-free time and access shape modality choice?"},{"id":"section-9","level":2,"title":"Preserve future options without losing the opportunity to control disease now"},{"id":"section-10","level":2,"title":"Anti-CD38 sensitivity determines which evidence answers the clinical question"},{"id":"section-11","level":3,"title":"How do monotherapy and doublet evidence inform different treatment choices?"},{"id":"section-12","level":3,"title":"How should survival curves, censoring and infection risk affect interpretation?"},{"id":"section-13","level":3,"title":"Tal-P rationale is not the same question as adding pomalidomide to talquetamab–daratumumab"},{"id":"section-14","level":2,"title":"Alternatives remain relevant when sensitivity, toxicity or access changes the choice"},{"id":"section-15","level":3,"title":"ADC selection exchanges one burden for another"},{"id":"section-16","level":3,"title":"Changing mechanism is proposed, not a validated universal sequence"},{"id":"section-17","level":2,"title":"Shared care and infrastructure determine whether community treatment is feasible"},{"id":"section-18","level":3,"title":"Prophylaxis preferences depend on the delivery environment"},{"id":"section-19","level":3,"title":"Restart rules, eligibility and referral remain imperfectly resolved"},{"id":"section-20","level":3,"title":"Daily burden can exceed the toxicity grade"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":9},{"id":"F9","shared_claims":1}],"id":"T1","label":"Primary endpoint: Progression Free Survival (PFS)"},{"findings":[{"id":"F1","shared_claims":5}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":2},{"id":"F7","shared_claims":2},{"id":"F8","shared_claims":11}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F8","shared_claims":6},{"id":"F9","shared_claims":5},{"id":"F10","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":14},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F8","shared_claims":1},{"id":"F9","shared_claims":1},{"id":"F12","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F4","shared_claims":1},{"id":"F8","shared_claims":2},{"id":"F9","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T18:16:20.310116Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T18:27:00Z","record_hash":"512f5c8f1b5964f3d3005b394400e14951408ada53361ab0e9129bbd304e2a01","release_hash":"1a9ff8de97c0fc1257820dae8de8798ac613757bec80c7f739d0c4db01274802","report_id":"erudio-nct06208150","run_id":"184b5c03-8f24-4819-b409-9f7e1d0b61d0","schema_version":"5.0","slug":"monumental-6-06208150","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"MonumenTAL-6 asks whether talquetamab with teclistamab or pomalidomide delays progression versus standard triplets in relapsed or refractory myeloma after anti-CD38 antibody and lenalidomide exposure. Commentary comes from X posts, podcasts and YouTube discussions, including physicians in hematology and oncology. The discussion turns on who needs dual targeting, particularly in high-risk or visceral extramedullary disease, and whether finite bispecific treatment preserves benefit. Infection prevention and access to continuing immune support also shape questions about bispecific adoption.","meta_description":"67 sources screened · 539 verified statements (334 from clinicians verified by NPI or staff page) from 43 sources · 12 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-35b864de35d26282d483"],"id":"F4","paraphrase":"An X thread asked whether talquetamab should be given for a defined maximum duration, in connection with MonumenTAL-6.","publication_caveats":{"reason":"Source-specific publication caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"x_thread","source_date":"2026-06-13","title":"Finite duration and response-adapted spacing attract support, but the optimal stopping point and preserved benefit remain uncertain"},{"cited_claim_ids":["claim-c2bfba604b4104ede0f7"],"id":"F8","paraphrase":"A podcast discussion asked whether MajesTEC-3 findings apply at first or second relapse after anti-CD38 exposure or in anti-CD38-refractory disease.","publication_caveats":{"reason":"Source-specific publication caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"podcast","source_date":"2026-09-03","title":"Prior anti-CD38 exposure versus refractoriness changes comparator relevance, daratumumab reuse and interpretation of alternative bispecific evidence"}]},"publication":{"approved_at":"2026-10-31T18:27:00Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":67},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.","Not yet captured in this edition: a view on one-time cellular therapy versus continuous bispecific treatment and their quality-of-life trade-offs in relapsed myeloma.","Not yet captured in this edition: a view on strict infection precautions qualifying the practical accessibility of bispecific treatment in early-relapse myeloma.","Not yet captured in this edition: a view on belantamab alternatives when eligibility, infection risk or access limits T-cell-directed treatment in early relapsed myeloma.","Not yet captured in this edition: a view on multi-antigen targeting in later-line myeloma and uncertainty about durability, resistance prevention and cure.","Not yet captured in this edition: a remark on separately presented evidence for one-time cellular therapy versus continuous bispecific treatment in relapsed or refractory myeloma.","Not yet captured in this edition: a view on strict infection precautions despite the feasibility of delivering bispecific treatment in any center, including early relapse.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","257 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are not a representative sample of all HCP opinion. Searches emphasized the trial identifier and recognized names, so discussion that never named the trial, used different terminology or appeared outside those searches may be missing. Some potentially relevant passages were not fully assessed; absence from this report should not be read as absence of a view.","No full publication for NCT06208150 was discovered, and no protocol document was available from ClinicalTrials.gov. The July 2026 topline discussion described a first interim analysis without a congress presentation, trial-specific safety detail or disclosed data cutoff at that time. The released OS estimate lacked a confidence interval and p-value in that account. These limits constrain interpretation of both enthusiasm and adoption concerns.","Statements span different interviews, posts, development stages and clinical settings. An account of ongoing recruitment, completed accrual, anticipated results or future approval describes that source’s setting; dates alone do not establish a change of mind or disagreement.","MonumenTAL-2, RedirecTT-1, MonumenTAL-3, MajesTEC-3, MajesTEC-9 and CAR T studies inform the discussion but are not MonumenTAL-6 results. Their populations, regimens, dosing, follow-up and comparators differ. Informal comparisons and sequencing observations do not establish head-to-head superiority or an optimal sequence.","Some spoken numerical accounts remain ambiguous or inconsistent. These include a high-risk control estimate, a 12-month PFS description in the ReDIRECT TT1 discussion, comparator labels differing from the registered EPd/PVd comparison, and an account of death-risk reduction that differs from the OS HR reported elsewhere. The report preserves those accounts as attributed statements rather than reconciling them into new estimates.","Reposts, quoted posts, press-release summaries and media digests are not additional independent clinical endorsements. Organizations and automated accounts are distinguished from HCPs, and another party’s findings or opinion remain attributed to that party when relayed.","Four speakers are described in the sources as involved in MonumenTAL-6. Their statements are not treated as independent external assessments or given additional evidentiary weight because of that involvement.","Several discussion passages cannot be assigned to a named speaker. Their views remain attributed to the episode or discussion, without assuming that they represent a new participant, a separate endorsement or disagreement with another person in that source.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Some passages describe personal treatment experience or relay an unnamed oncologist’s reasoning. They provide patient-support and treatment-decision context, not separately identified direct HCP testimony or comparative outcome evidence.","Toxicity assessments are not uniform. Some accounts emphasize improvement with dose modification or holds, while others emphasize persistent symptoms or events unresolved at a study cutoff. Different studies, follow-up and individual experiences should not be collapsed into either universal reversibility or permanent irreversibility."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":7,"publication":0,"registry":1,"regulatory":0,"x_thread":28,"x_video":0,"youtube":7},"by_evidence_role":{"commentary":42,"methods":1},"count":43,"evidence_window":{"end":"2026-10-29","start":"2024-01-08"},"retrieval_snapshot":"2026-10-31T14:02:23.789904Z","timeline":[{"count":1,"week":"2024-W02"},{"count":1,"week":"2024-W15"},{"count":1,"week":"2024-W24"},{"count":1,"week":"2024-W41"},{"count":1,"week":"2025-W09"},{"count":1,"week":"2025-W18"},{"count":3,"week":"2025-W49"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2026-W18"},{"count":2,"week":"2026-W22"},{"count":1,"week":"2026-W24"},{"count":2,"week":"2026-W25"},{"count":1,"week":"2026-W27"},{"count":7,"week":"2026-W30"},{"count":3,"week":"2026-W31"},{"count":2,"week":"2026-W32"},{"count":1,"week":"2026-W33"},{"count":1,"week":"2026-W36"},{"count":4,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":3,"week":"2026-W41"},{"count":2,"week":"2026-W42"},{"count":1,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06208150:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06208150:context","quote_policy":"short_quote_link_out"},{"id":"openfda:9001355e-003d-4d4e-b4ce-337e0fd14952:20251008","quote_policy":"short_quote_link_out"},{"id":"openfda:3c222961-5398-4185-b2d0-defe90230094:20260901","quote_policy":"short_quote_link_out"},{"id":"openfda:54e0f974-ccee-44ea-9254-40e9883cee1e:20260310","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-7eeegxgy3hkpipqnlzr7na4c-3mrctwf4yrm2i","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3mrd5tdgtyc2q","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ffhfzwr3igtwt4y7zdompvjv-3mrctpyj76y2a","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:3e4093","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:6b4f59","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:909715","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:983dfa","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:b1852d","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:ed2405","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:ff8188","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1754977365849952590:895fb542-34bb-4b68-9201-0176631867bc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1778450850265883045:542d8ed1-f4f0-4a64-a3b2-0f6cb4e8bfc3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1794298212414615639:22318eec-6815-42c3-8998-262a6b74f145","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1801212289237848073:4c59b112-fa60-4b2b-8135-e2336860f734","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997798777298809024:f4f75b23-fa74-48b4-9915-c5440844bb52","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997798906797904063:77f82916-83b3-41d9-b58d-38a9398fea5a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997799433384386940:d873c731-3ea2-4129-9ddb-825f90dfebb6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049575229769588819:28ba7f51-5d3d-4443-b3bb-41b9140e8c46","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060134524843921530:cb413489-bbac-4992-a12f-d8ff8bfa6008","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060481325182992642:04a40332-1c4d-4815-8b1f-5a468e603828","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065774049968443767:8e528f26-ca7d-4b2b-be01-595cd438f430","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2068191373959004539:b94765b3-2726-47c5-a573-3ac8a6dbf927","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080277137806831657:8024dbe8-8543-4563-a264-6f37e1cabe1c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080290434153078984:a6101329-528a-4eae-98c3-ff00c43c2f56","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080307182827172163:838d52e6-972e-45ef-bd8a-e8d17fde519f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080308162821775633:a4a21aa7-11d0-40c1-9527-e3f192b58e96","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080314733790454238:a5669bd1-2014-4868-b36e-5d9cb502d8d0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080320960335618316:78368572-cfde-4eb2-9705-a60ef54000a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080327560697950671:c4d64dc3-d114-4852-bed1-fc742c1bb5d3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080336364248199294:c34339fc-72f5-40ce-9ea2-0b738937d00f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080386347542385094:60d4ddba-6a3c-458e-b1de-3a96b5eb0da8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080405517571395939:aaf2858c-ec8d-4316-b63e-491907f008b0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080449863083278385:e9567981-466d-4d70-aa2e-bfc829049b4e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080456745130889699:46eddd0e-54a4-4d4d-b4ab-6a69357e4f6b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080477405785792752:34b311fd-fdd9-4390-bc10-dc1cc87a8f20","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080687234357805296:4bc68064-a3e1-4f40-a98c-3bb6f25968ae","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2081205088845279437:71a00108-a192-40b5-970f-c6af83ff5532","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2081623835984695788:38fd1e63-be60-4630-97c0-edd74e85b714","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2081683295222239359:ff28f221-c8da-4fcd-ad1a-151e3f10719a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2081748962630082797:bc489cca-c4a4-47e8-a259-5d32fe0afcb5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2081749097258623140:56e21003-bdb9-48b5-87f4-c33d82b45a70","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2084709452205162911:d1874f85-db15-4ff3-b39a-565be39d233f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2085314049357807694:56175791-ea9e-4cd7-9040-118cc091f051","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2086063226043936801:602e9702-f0be-4485-8e28-d366d507063a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2087525522158874868:a195dc09-ef64-4fbe-9ad0-552e87162411","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2087705703008141408:1576afee-494a-4ff3-881e-27b5ca7937a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089714394007519261:65ad1914-6612-400e-ad5c-a8b619ed7910","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102780644627792067:f7c3bbf9-32f5-4a04-92d6-bac5050e3e37","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102783338725450166:d01ad009-fe5b-4ef5-a76e-616a42df6190","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102787924811202646:d32c5798-83f8-45d6-bb0b-9ff91ea871a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102788185164017850:eaf57bad-5ce3-4fad-9f08-ed8bed2986ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102899187511877652:fc1268f9-9b06-49a6-96c1-fb7c9bdf2386","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104080558888525865:7c97f7a0-40cf-452d-992e-c6beb381cd2f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105020950383366165:cd3e4bf4-3917-4f04-88a1-c5da55e549b8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107162613054574621:c230a8c8-4a7c-49a0-9bd2-e9b1cf1ee4c6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108427529308803402:6abdf436-bec1-4321-8e25-1b6a27eda7e7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108646614352928806:b8aa260a-d374-4832-b6e4-79aadc57aa09","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110707012703265033:7c5da280-7948-49f7-87b3-28efa052c3a6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111115915308007560:f3eb8266-8988-48ff-99be-00a954ba34e7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115631148470817161:52d22c4a-6ce8-47d8-8818-17af3ab0ad26","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:9lQjvmL4j3w","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:JQagT2PSRdg","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:X0xAQbQSaaI","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:iFerrL9eEwM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:jeGVz76hVM8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:qe-qqQMoZvs","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:yq2h3uINtMM","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":3,"linkedin_post":0,"other":0,"podcast":7,"publication":0,"registry":0,"regulatory":0,"x_thread":50,"x_video":0,"youtube":7},"by_evidence_role":{"commentary":67},"count":67,"evidence_window":{"end":"2026-10-29","start":"2024-01-08"},"retrieval_snapshot":"2026-10-31T14:02:23.789904Z","timeline":[{"count":1,"week":"2024-W02"},{"count":1,"week":"2024-W06"},{"count":1,"week":"2024-W15"},{"count":1,"week":"2024-W21"},{"count":1,"week":"2024-W24"},{"count":1,"week":"2024-W41"},{"count":1,"week":"2025-W09"},{"count":1,"week":"2025-W18"},{"count":3,"week":"2025-W49"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2026-W18"},{"count":2,"week":"2026-W22"},{"count":1,"week":"2026-W24"},{"count":2,"week":"2026-W25"},{"count":1,"week":"2026-W27"},{"count":18,"week":"2026-W30"},{"count":5,"week":"2026-W31"},{"count":4,"week":"2026-W32"},{"count":3,"week":"2026-W33"},{"count":1,"week":"2026-W34"},{"count":1,"week":"2026-W36"},{"count":6,"week":"2026-W39"},{"count":2,"week":"2026-W40"},{"count":4,"week":"2026-W41"},{"count":3,"week":"2026-W42"},{"count":1,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Talvey"],"label":"talquetamab","slug":"talquetamab"},{"brand_names":["Pomalyst"],"label":"pomalidomide","slug":"pomalidomide"},{"brand_names":["Tecvayli"],"label":"teclistamab","slug":"teclistamab"},{"reason":"Unmapped registry intervention: elotuzumab","status":"unmapped"},{"brand_names":["Decadron","Dexacen-4","Dexone","Hemady","Hexadrol","Taperdex"],"label":"dexamethasone","slug":"dexamethasone"},{"brand_names":["Velcade"],"label":"bortezomib","slug":"bortezomib"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Multiple myeloma","slug":"multiple-myeloma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"MonumenTAL-6","aliases":["MonumenTAL-6","A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide","64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom"],"brief_title":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Multiple Myeloma"],"display_condition":"relapsed or refractory multiple myeloma","display_interventions":[["talquetamab","pomalidomide"],["talquetamab","teclistamab"]],"enrollment":{"count":838,"type":"ACTUAL"},"interventions":[{"name":"Talquetamab","synonyms":["JNJ-64407564","Talvey"],"type":"DRUG"},{"name":"Pomalidomide","synonyms":["Pomalyst","Imnovid"],"type":"DRUG"},{"name":"Teclistamab","synonyms":["JNJ-64007957","Tecvayli"],"type":"DRUG"},{"name":"Elotuzumab","synonyms":["Empliciti"],"type":"DRUG"},{"name":"Dexamethasone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Bortezomib","synonyms":["Velcade"],"type":"DRUG"}],"nct_id":"NCT06208150","official_title":"64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2026-04-01","type":"ACTUAL"},"primary_endpoints":[{"description":"PFS is defined as the duration from the date of randomization to either progressive disease or death, whichever comes first.","measure":"Progression Free Survival (PFS)","timeFrame":"Up to 3 years 5 months"}],"registered_date":{"date":"2024-01-17","type":"ACTUAL"},"registry_last_updated":"2026-09-25","registry_url":"https://clinicaltrials.gov/study/NCT06208150","short_name":"MonumenTAL-6","short_name_basis":"registry_acronym","sponsor":"Janssen Research & Development, LLC","start_date":{"date":"2024-01-22","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"64407564MMY3009","type":"sponsor_study_id"},{"domain":"EUCT number","id":"2022-502446-27-00","type":"registry"}],"study_type":"INTERVENTIONAL"}}}